lower than that, based on the data that we had, we really did not think that anyone could really see the difference between formulations at a lower dose simply because of lack of sensitivity of the assays to even detect that in the blood.
Obviously, endogenous baselines are always a problem. You need to be able to deal with correcting for the baseline if necessary or deciding whether baseline correction is necessary.
The feedback inhibition or feedback control of the endogenous production is an important concept which relates to the baseline still.
Some of these under normal conditions have circadian or other types of rhythms or variability throughout the day and that has to be taken into account.
And some of these are claimed to be either linear or nonlinear pharmacokinetics which, as I said, is another consideration that controls the sensitivity of the test.
So today, as far as the agenda goes, we will have two case studies, the first being a case study on levothyroxine with actually two speakers in that case